Advanced search
Publication Cover
Expert Review of Anti-infective Therapy Volume 2, 2004 - Issue 1
Submit an article Journal homepage
16
Views
8
CrossRef citations to date
0
Altmetric
Review

Emerging trends in infections among renal transplant recipients

Nestor F Varon Division of Infectious Diseases, Wayne State University School of Medicine, Detroit, MI, USA. [email protected]
&
George J Alangaden Division of Infectious Diseases, Wayne State University School of Medicine, Detroit, MI, USA. [email protected]
Pages 95-109 | Published online: 10 Jan 2014

References

  • Simon DM, Levin S. Infectious complications of solid organ transplantations. Infect. Dis. Clin. North Am. 15(2), 521–549 (2001).
  • Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl. J Med. 338(24), 1741–1751 (1998).
  • Patel R. Infections in recipients of kidney transplants. Infect. Dis. Clin. North Am. 15(3), 901–953 (2001).
  • ••One of the most extensive and completereview published recently about infections in renal transplantation.
  • Ahsan N, Holman MJ, Yang HC. Efficacy of oral ganciclovir in prevention of cytomegalovirus infection in post-kidney transplant patients. Clin. Transplant 11, 633–639 (1997).
  • Brennan DC, Garlock KA, Singer GG, et al. Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients. Transplantation 64,1843–1846 (1997).
  • Chan L, Gaston R, Hariharan S. Evolution of immunosuppression and continued importance of acute rejection in renal transplantation. Am. J Kidney Dis. 38(6 Suppl. 6), S2—S9 (2001).
  • Gaston RS. Maintenance immunosuppression in the renal transplant recipient: an overview. Am. J Kidney Dis. 38(6 Suppl. 6), S25—S35 (2001).
  • Kaufman DB, Leventhal JR, Koffron AJ, et al. A prospective study of rapid corticosteroid elimination in simultaneous pancreas—kidney transplantation: comparison of two maintenance immunosuppression protocols: tacrolimusimycophenolate mofetil versus tacrolimusisirolimus. Transplantation 73 (2), 169–177 (2002).
  • Vincenti F, Stock E Be novo use of sirolimus in immunosuppression regimens in kidney and kidney—pancreas transplantation at the University of California, San Francisco. Transplant Proc. 35(3 Suppl), 5183—S186 (2003).
  • Swanson SJ, Hale DA, Mannnon RB, et al. Kidney transplantation with rabbit antithymocyte globulin induction and sirolimus monotherapy. Lancet 360, 1662–1664 (2002).
  • Husain S, Singh N. The impact of novel immunosuppressive agents on infections in organ transplant recipients and the interactions of these agents with antimicrobials. Clin. Infect. Dis. 35 (1), 53–61 (2002).
  • Sarmiento JM, Dockrell DH, Schwab TR, Munn SR, Paya CV. Mycophenolate mofetil increases cytomegalovirus invasive organ disease in renal transplant patients. Clin. Transplant 14,136–138 (2000).
  • Mathew TH. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: results at 3 years. Tricontinental Mychophenolate Mofetil Renal Transplantation Study Group. Transplantation 65,1450–1454 (1998).
  • Bernabeu-Wittel M, Naranjo M, Cisneros JM, et al. Infections in renal transplant recipients receiving mycophenolate versus azathioprine-based immunosuppression. Ear. j Clin. MicrobioL Infec. Dis. 21(3), 173–180 (2002).
  • Munoz MA, Andres A, Gallego R, et al. Mycophenolate mofetil immunosuppressive therapies increase the incidence of cytomegalovirus infection in renal transplantation. Transplant Proc. 34(1), 97 (2002).
  • Abbott KC, Hypolite IC), Viola R, et al. Hospitalizations for cytomegalovirus disease after renal transplantation in the United States. Ann. EpidernioL 12(6), 402–409 (2002).
  • Schnitzler MA, Lowell JA, Hardinger KL, Boxerman SB, Bailey TC, Brennan DC. The association of cytomegalovirus sero-pairing with outcomes and costs following cadaveric renal transplantation prior to the introduction of oral ganciclovir CMV prophylaxis. Am. J Transplant. 3 (4), 445–451 (2003).
  • Rothwell WS, Gloor JM, Morgenstern BZ, Milliner DS. Disseminated varicella infection in pediatric renal transplant recipients treated with mycophenolate mofetil. Transplantation 68,158–161 (1999).
  • Oz HS, Hughes WT. Novel anti-Pneurnocystis carinii effects of immunosuppressant mycophenolate mofetil in contrast to provocative effects of tacrolimus, sirolimus and dexamethasone. J Infect. Dis. 175, 901–904 (1997).
  • Troppmann C, Pierce GL, Gandhi MM, Gallay BJ, McVicar JP, Perez RV. Higher surgical wound complication rates with sirolimus immunosuppression after kidney transplantation: a matched-pair pilot study. Transplantation 76(2), 426–429 (2003).
  • Abbott KC, Oliver JD, Hypolite I, et al. Hospitalizations for bacterial septicemias after renal transplantation in the United States. Am. I NephroL 21,122–127 (2001).
  • Schmaldienst S, Dittrich E, Walter H. Horl. Urinary tract infections after renal transplantation. Carr. Opin. UroL 12, 125–130 (2002).
  • Muller V, Becker G, Delfs M, et al. Do urinary tract infections trigger chronic kidney transplant rejection in man?J Urol. 159(6), 1826–1829 (1998).
  • Brown E Urinary tract infections in renal transplant recipients. Carr. Infect. Dis. Rep. 4,525–528 (2002).
  • Takai K, Tollemar J, Wilczek HE, Groth CG. Urinary tract infections following renal transplantation. Clin. Transplant. 12(1), 19–23 (1998).
  • •One of the largest series with long-term follow-up published about urinary tract infection in renal transplantation.
  • Oguz Y, Bulucu F, Oktenli C, Doganci L, Vural A. Infectious complications in 135 Turkish renal transplant patients. Cent. Eur. PubL Health 10,153–156 (2002).
  • Singh N. Fungal infections in the recipients of solid organ transplantation. Infect. Dis. Clin. North Ara 17(1), 113–134 (2003).
  • Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis. Clin. Infect. Dis. 30(4), 662–678 (2000).
  • Munoz E Management of urinary tract infection and lymphocele in renal transplant recipients. Clin. Infect. Dis. 33\(Suppl. 1), S53—S57 (2001).
  • Maki DG, Fox BC, Kundz J, Sollinger HVV, Belzer FO. A prospective randomized double-blind study of trimethoprim—sulfamethaxazole for prophylaxis of infection in renal transplantation: side effects of trimethroprim—sulfamethoxazole, interaction with cyclosporin. J Lab. Clin. Med. 119,11–24 (1992).
  • Fox BC, Sollinger HW, Belzer FO, Maki DG. A prospective randomized double-blind study of trimethoprim—sulfamethaxazole for prophylaxis of infection in renal transplantation: clinical efficacy, absorption of trimethroprim—sulfamethoxazole, effects on the microflora, cost benefit of prophylaxis. Am. J Med. 89,255–274 (1990).
  • Moyes Neto M, Costa RS, Reis MA, et al. Use of ciprofloxacin as a prophylactic agent in urinary tract infections in renal transplant recipients. Clin. Transplant. 11, 446–452 (1997).
  • Tolkoff-Rubin NE, Rubin RH. Urinary tract infection in the immunocompromised host. Lessons from kidney transplantation and the AIDS epidemic. Infect. Dis. N. Arn. 11,707–717(1997).
  • Kaminska W, Patzer J, Dzierzanowska D. Urinary tract infections caused by endemic multi-resistant Enterobacter cloacae in a dialysis and transplantation unit. J Hosp. Infect. 51(3), 215–220 (2002).
  • Paterson DL. Serious infections caused by enteric Gram-negative bacilli-mechanisms of antibiotic resistance and implications for therapy of Gram-negative sepsis in the transplanted patient. Sernin. Respir. Infect. 17(4), 260–264 (2002).
  • Patel R, Allen SL, Manahan JM, et al. Natural history of vancomycin-resistant enterococcal colonization in liver and kidney transplant recipients. Liver Tramp]. 7(1), 27–31 (2001).
  • Zhanel GG, Laing NM, Nichol KA, et al. Antibiotic activity against urinary tract infection (UT0 isolates of vancomycin-resistant enterococci (VRE): results from the 2002 North American Vancomycin Resistant Enterococci Susceptibility Study (NAVRESS). j Antimicrob. Chermother. 52(3), 382–388 (2003).
  • Humar A, Ramcharan T, Denny R, Gillingham KJ, Payne WD, Matas AJ. Are wound complications after a kidney transplant more common with modern immunosuppression? Transplantation 72, 1920–1923 (2001).
  • Lapchik MS, Filho AC, Pestana Joa, Filho APS, Wey SB. Risk factors for nosocomial urinary tract and post operative wound infections in renal transplant patients: a matched-pair case control study. J Urol. 147,944–948 (1992).
  • Mandell GL, Bennet JE, Dolin R (Eds), Churchill Livingstone, PA, USA, 3148–3158 (2000).
  • Ahsan N. Introduction (BK virus). Graft 5 (Suppll, S6 (2002).
  • Geiger X, Chang I, Coral S, Helderman JH, Fogo A. A 50-year-old man with persistent renal allograft dysfunction. Am. J Kidney Dis. 40(1), 210–217 (2002).
  • Mihatsch M, Steiger J, Nickeleit V. BK virus infection after kidney transplantation. Graft 5 (Suppl.), S46—S57 (2002).
  • •Recent and comprehensive review regarding BK virus infection in renal transplantation.
  • Hirsch HH, Knowles W, Dickenmann M, et al. Prospective study of polyomavirus type BK replication and nephropathy in renal transplant recipients. N Engl. J Med. 347,488–496. (2002).
  • Shah KV, Ahsan N. Polyomaviruses: an overview. Graft, 5 (Suppl.), S9—S18 (2002).
  • Howell D, Smith S, Butterly D, et al. Diagnosis and management of BK polyomavirus interstitial nephritis in renal transplant recipients. Transplantation 68, 1279–1288 (1999).
  • Hurault de Ligny B, Etienne I, Francois A, et al. Polyomavirus-induced acute tubulo-interstitial nephritis in renal allograft recipients. Transplant Proc. 32,2760–2761 (2000).
  • Ahuja M, Cohen E, Dayer A, et al. Polyoma virus infection after renal transplantation. Tiansplantation 71,896–899 ( 2001).
  • Nickeleit V, Hirsh HH, Binet IF, et al. Polyomavirus infection of renal allograft recipients: from latent infection to manifest disease. jAm. Soc. Nephrol. 1080–1089 (1999).
  • Drachenberg CB, Beskow CO, Cangro CB, et al. Human polyomavirus in renal allograft biopsies: morphologic findings and correlation with urine cytology. Human Pathology30 (8), 970–977 (1999).
  • Nickeleit V, Hirsh HH, Binet IF, et al. Testing for polyomavirus type BK DNA in plasma to identify renal-allograft recipients with viral nephropathy. N Engl.. 1. Med. 342,1309-1315 (2000).
  • Ling PL, Vats A, Green M. BK virus in pediatric solid organ transplant recipients. Pediatr. Transplant. 5,398 (2001).
  • Ramos E, Drachenberg CB, Portocarrero M, et al. BK virus nephropathy diagnosis and treatment: experience at the University of Maryland Renal Transplant Program. Clin. Transplant. 143–153 (2002).
  • Roskopf J, Fitzsimmons W, Ahsan N, Laskow D. The pharmacologic treatment of Human Polyomavirus infection. Graft 5(Suppl.) S88—S97 (2002).
  • Fishman JA. BK virus nephropathy — polyomavirus adding insult to injury. N Engl. Med. 347,527–530 (2002).
  • Randhawa P, Finkelstein S, Scantlebury V, et al. Human polyoma virus-associated interstitial nephritis in the allograft kidney. Transplantation 67,103–109 (1999).
  • Nickeleit V, Hirsch H, Zeiler M, et al. BK-virus nephropathy in renal transplants-tubular necrosis, MHC-class II expression and rejection in a puzzling game. Nephrol. Transplant. 15,324–332 (2000).
  • Becker BN, Becker YT, Leverson GE, Simmons WD, Sollinger HVV, Pirsch JD. Reassessing the impact of Cytomegalovirus infection in kidney and kidney—pancreas transplantation. Am. J Kidney Dis. 39(5), 1088–1095 (2002).
  • ••Large study of 1424 patients evaluatingthe changes in cytomegalovirus infection in the antiviral prophylaxis era.
  • Brennan DC. Cytomegalovirus in renal transplantation. jAm. Soc. Nephrol. 12, 848–855 (2001).
  • Arend SM, Westendorp RG, Kroon FP, et al. Rejection treatment and cytomegalovirus infection as risk factors for Pneurnocystis carinii pneumonia in renal transplant recipients. Clin. Infect. Dis. 22, 920–925 (1996).
  • Mandell GL, Bennet JE, Dolin R (Eds), Churchill Livingstone, PA, USA, 184–221 (2000).
  • Isada CM, Kasten BL, Goldman MP, Gray LD, Aberg JA. Disease syndromes & organisms: Cytomegalovirus. In: Infectious Diseases Hand Book (5th Edition). Lexi-Comp, OH, USA, 102–107 (2003).
  • Musch DC, Martin DF, Gordon JF, Davis MD, Kuppermann BD. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. N Engl. J Med. 337,83–90 (1997).
  • Martin DF, Sierra-Madero J, Walmsley S, et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis, for the Valganciclovir Study Group. N Engl. J Med. 346 (15), 1119–1126 (2002).
  • Brennan DC, Garlock KA, Lippmann BA, et al. Control of cytomegalovirus associated morbidity in renal transplant patients using intensive monitoring and either preemptive or deferred therapy. J Am. Soc. Nephrol. 8, 118–125 (1997).
  • Singh N. The impact of current transplantation practices on the changing epidemiology of infections in transplant recipients. Lancet Infect. Dis. 3 (3), 156–161 (2003).
  • Jassal SV, Roscoe JM, Zaltzman JS, et al. Clinical practice guidelines: prevention of cytomegalovirus disease after renal transplantation. J Am. Soc. Nephrol. 9, 1697–1708 (1998).
  • Lowance D, Neumayer HH, Legendre CM, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International valacyclovir cytomegalovirus prophylaxis transplantation study group. N Engl.. 1. of Med. 340,1462-1470 (1999).
  • Pescovitz MD, Rabkin J, Merton RM, et al. Valganciclovir results in improved oral absoption of ganciclovir in liver transplant recipients. Antirnicrob. Chernother. 44 (10), 2811–2815 (2000).
  • Paya CV. (on behalf of the valganciclovir Solid Organ Trasplant Study Group). A randomized, double-blind, double-dummy, active-comparator controlled multi-center study of the efficacy and safety of valganciclovir versus oral ganciclovir for prevention of CMV disease in 372 high-risk (D+/R-) heart, liver and kidney recipients. Proceedings of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (7CAAC), San Diego, USA (2002).
  • Pescovitz M, Paya C, Humar A. Valganciclovir for the prevention of CMV disease: 12 months follow-up of a randomized trial of 364 D+/R-transplant recipients. Am. J Transplant 3 (Supp1.5), (2003) (Abstract 575).
  • Cianco G, Burke G, Zvi L. Valganciclovir prophylaxis for cytomegalovirus disease in kidney and simultaneous pancreas—kidney transplant recipients. Am. J Transplant 3 (Supp1.5), (2003) (Abstract 1379).
  • Gelone D, Cibrik D, Vogler S. Comparative efficacy and safety of low dose valganciclovir vs. oral ganciclovir for the prevention of cytomegalovirus disease in renal allograft recipients. Am. J Transplant. 3 (Supp1.5), (2003) (Abstract 1400).
  • Isada CM, Yen-Lieberman B, Lurain NS, et al. Clinical characteristics of 13 solid organ transplant recipients with ganciclovir-resistant cytomegalovirus infection. Transplant. Infect. Dis. 4(4), 189–194 (2002).
  • Abbott KC, Ypolite I, Poropatich RK, et al. Hospitalizations for fungal infections after renal transplantation in the United States. Transplant. Infect. Dis. 3(4), 203–221 (2001).
  • Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin. Infect. Dis. 24(6), 1122–1128 (1997).
  • Bodey GP, Mardani M, Hanna HA, et al. The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am.j Med. 112(5), 380–385 (2002).
  • Husain S, Tollemar J, Dominguez EA. Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, case-controlled study. Transplantation 75(12), 2023–2029 (2003).
  • Gordon SM, LaRosa SP, Kalmadi S, et al. Should prophylaxis for Pneurnocystis carinii pneumonia in solid organ transplant recipients ever be discontinued? Clin. Infect. Dis. 28(2), 240–246 (1998).
  • Kaufman DB, Leventhal JR, Gallon LG, et al. Technical and immunological progress in simultaneous kidney pancreas transplantation. Surgery132,545-554 (2002).
  • Sollinger HW, Ploeg RJ, Eckhoff DE, et al. Two hundred consecutive simultaneous pancreas—kidney transplants with bladder drainage. Surgery 114(4), 736–743 (1993).
  • Becker BN, Odorico JS, Becker YT, et al. Simultaneous pancreas—kidney and pancreas transplantation. J Am. Soc. NephroL 12,2517–2527 (2002).
  • Pirsch JD, Odorico JS, d'Alessandro AM, et al. Post transplant infection in enteric versus bladder drained simultaneous pancreas kidney transplant recipients. Transplantation 66,1746–1750 (1998).
  • Smets YFder Pij1 JW, van Dissel JT, Ringers J, de Fijter JW, Lemkes HH, van. Infectious disease complications in simultaneous pancreas kidney transplantation. Nephro. DiaL Transplant 12,764–771 (1997).
  • Steurer W, Bonatti H, Obrist P, et al. Incidence of intra-abdominal infection in a consecutive series of 40 enteric-drained pancreas transplant with FK50 6 and MMF immunosuppression. Transplant 13(Suppl), S195—S198 (2000).
  • •Descriptive report of the clinical and microbiological features of intrabdominal infections in SPK.
  • Sutherland DE, Gruessner RW, Dunn DL, et al Lessons learned from more than 1,000 pancreas transplants at a single institution. Ann. Surg. 233 (4), 463–501 (2001).
  • Beneditti E, Troppmann C, Gruessner AC, et al. Pancreas graft loss caused by intrabdominal infection. Risk factor for a subsequent pancreas retransplantation. Arch. Surg. 131(10), 1054–1060 (1996).
  • Beneditti E, Gruessner AC, Troppmann C. Intrabdominal fungal infections after pancreatic transplantation: incidence, treatment and outcome. J Am. Coll. Surg. 183(4), 307–316 (1996).
  • Roland M, Stock P. Review of solid-organ transplantation in HIV infected patients. Transplantation 75 (4), 425–429 (2003).
  • Ahuja TS, Borucki M, Grady J. Highly active antiretroviral therapy improves survival of HIV-infected hemodialysis patients. Am. J Kidney Dis. 36 (3), 574–580 (2000).
  • Kuo PC, Stock PG. Transplantation in the HIV+ patient. Am. J Transplant. 1(1), 13–17 (2001).
  • Swanson SJ, Kirk AD, Ko CVV, Jones CA, Agodoa LY, Abbott KC. Impact of HIV seropositivity on graft and patient survival after cadaveric renal transplantation in the United States in the pre-highly active antiretroviral therapy (HAART) era: an historical cohort analysis of the United States Renal Data System. Transplant Infect. Dis. 4(3), 144–147 (2002).
  • Murphy B, Carlson L, Rohal S, et al Renal transplantation in HIV-infected recipients: Twenty-three cases in the HAART era. J Am. Soc. NephroL 13,11A (2002).
  • Ahuja TS, O'brien WA. Special issues in the management of patients with ESRD and HIV infection. Am. J Kidney Dis. 41(2), 279–291 (2003).
  • Halpern S, Ubel P, Caplan A. Solid organ transplantation in HIV infected patients. N Engl.. 1. Med. 347(4), 284–287 (2002).
  • Zacks SL, Fried MW. Infections in patients with chronic renal failure: hepatitis B and C and renal failure. Infect. Dis. Clin. North Am. 15(3), 877–899 (2001).
  • •Extensive and in-depth review about hepatitis C and B infection in chronic renal failure and renal transplant recipients.
  • Alter MJ, Kuhnert WL, Finelli L. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. MMWR Recomm. Rep. 52 (RR-3), 1–13 (2003).
  • Modlin CS, Goldfarb DA, Novick AC. The use of expanded criteria cadaver and liver donor kidneys for transplantation. UroL Clin. North Am. 28(4), 687–707 (2001).
  • Abbott KC, Bucci JR, Matsumoto CS. Hepatitis C and renal transplantation in the era of modern immunosuppression. J Am. Soc. NephroL 14(11), 2908–2918 (2003).
  • Fabrizi F, Martin P, Ponticelli C. Hepatitis C virus infection and renal transplantation. Am. J Kidney Dis. 38(5), 919–934 (2001).
  • Gana E, Pilmore H. Management of chronic viral hepatitis before and after renal transplantation. Transplantation 74(4) 427–437 (2002).
  • Einollahi B, Hajarizadeh B,Bakhtiari S, et al. Pretransplant hepatitis C virus infection and its effect on the posnransplant course of living renal allograft recipients. Gastroenterol Hepatol. 18(7), 836–840 (2003).
  • Kamar N, Sandres-Saune K, Selves J, Durand D, Izopet J, Rostaing L. Is there a place for ribavirin in the treatment for renal transplant patients infected by hepatitis C virus? Nephrologie 24 (2), 89–94 (2003).
  • Schaffner A. Pretransplant evaluation for infections in donors and recipients of solid organs. ClirL Infect. Dis. 33 (Suppl. 1), S9—S14 (2001).
  • Iwamoto M, Jernigan DB, Guasch A, et al Transmission of West Nile virus from an organ donor to four transplant recipients — West Nile Virus in Transplant Recipients Investigation Team. N Engl. J Med. 348(22), 2196–2203 (2003).
  • CDC. Detection of West Nile Virus in blood donations — United States, 2003. MMWR Morb. Mortal. Wkly Rep. 52(32), 769–772 (2003).
  • Avery RK, Ljungman P Prophylactic measures in the solid-organ recipient before transplantation. Clih. Infect. Dis. 33 (Suppl. 1), S15—S21 (2001).
  • Mokine DC. Vaccines for transplant recipients. Infect. Dis. ClirL North Am. 15 (1), 273–305 (2001).
  • Plotkin SA. Is there a formula for an effective CMV vaccine?./ ClirL Vim]. 25 (Suppl. 2), S13—S21 (2002).
  • Sande MA (Eds). The Sanford Guide to Antimicrobial Therapy Antimicrobial Therapy Inc., VT, USA 104–110 (2003).

Website

  • Human organ and tissue transplantation. Executive board EB1112/5. 112th session 2 May 2003. Provisional agenda item 4.3. World Health Organization. www.who.int/ethics/topics/human_transplan t_report/en/ (Accessed on January 27/2004).
  • Important facts about kidney disease. American Kidney Foundation. www.kidneyfund.org/KidneyFacts/KidneyFac ts.htm (Accessed on January 27/2004).
  • US food and drug administration (FDA) news. www.fda.gov/ (Accessed on January 27/2004).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.